Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 322

1.

AT1R-AT2R-RXFP1 Functional Crosstalk in Myofibroblasts: Impact on the Therapeutic Targeting of Renal and Cardiac Fibrosis.

Chow BSM, Kocan M, Shen M, Wang Y, Han L, Chew JY, Wang C, Bosnyak S, Mirabito-Colafella KM, Barsha G, Wigg B, Johnstone EKM, Hossain MA, Pfleger KDG, Denton KM, Widdop RE, Summers RJ, Bathgate RAD, Hewitson TD, Samuel CS.

J Am Soc Nephrol. 2019 Sep 11. pii: ASN.2019060597. doi: 10.1681/ASN.2019060597. [Epub ahead of print]

PMID:
31511361
2.

Adrenoceptors-New roles for old players.

Michel MC, Bond RA, Summers RJ.

Br J Pharmacol. 2019 Jul;176(14):2339-2342. doi: 10.1111/bph.14701.

PMID:
31240712
3.
4.

BRL37344 stimulates GLUT4 translocation and glucose uptake in skeletal muscle via β2-adrenoceptors without causing classical receptor desensitization.

Mukaida S, Sato M, Öberg AI, Dehvari N, Olsen JM, Kocan M, Halls ML, Merlin J, Sandström AL, Csikasz RI, Evans BA, Summers RJ, Hutchinson DS, Bengtsson T.

Am J Physiol Regul Integr Comp Physiol. 2019 May 1;316(5):R666-R677. doi: 10.1152/ajpregu.00285.2018. Epub 2019 Mar 20.

PMID:
30892909
5.
6.

Drug-receptor kinetics and sigma-1 receptor affinity differentiate clinically evaluated histamine H3 receptor antagonists.

Riddy DM, Cook AE, Shackleford DM, Pierce TL, Mocaer E, Mannoury la Cour C, Sors A, Charman WN, Summers RJ, Sexton PM, Christopoulos A, Langmead CJ.

Neuropharmacology. 2019 Jan;144:244-255. doi: 10.1016/j.neuropharm.2018.10.028. Epub 2018 Oct 22.

PMID:
30359639
7.

Molecular pharmacology of GPCRs.

Langmead CJ, Summers RJ.

Br J Pharmacol. 2018 Nov;175(21):4005-4008. doi: 10.1111/bph.14474.

PMID:
30302756
8.

Rosiglitazone and a β3-Adrenoceptor Agonist Are Both Required for Functional Browning of White Adipocytes in Culture.

Merlin J, Sato M, Chia LY, Fahey R, Pakzad M, Nowell CJ, Summers RJ, Bengtsson T, Evans BA, Hutchinson DS.

Front Endocrinol (Lausanne). 2018 May 30;9:249. doi: 10.3389/fendo.2018.00249. eCollection 2018.

9.

Comparative genotypic and phenotypic analysis of human peripheral blood monocytes and surrogate monocyte-like cell lines commonly used in metabolic disease research.

Riddy DM, Goy E, Delerive P, Summers RJ, Sexton PM, Langmead CJ.

PLoS One. 2018 May 10;13(5):e0197177. doi: 10.1371/journal.pone.0197177. eCollection 2018.

10.

Divergent effects of strontium and calcium-sensing receptor positive allosteric modulators (calcimimetics) on human osteoclast activity.

Diepenhorst NA, Leach K, Keller AN, Rueda P, Cook AE, Pierce TL, Nowell C, Pastoureau P, Sabatini M, Summers RJ, Charman WN, Sexton PM, Christopoulos A, Langmead CJ.

Br J Pharmacol. 2018 Nov;175(21):4095-4108. doi: 10.1111/bph.14344. Epub 2018 Jun 3.

PMID:
29714810
11.

INSL5 activates multiple signalling pathways and regulates GLP-1 secretion in NCI-H716 cells.

Ang SY, Evans BA, Poole DP, Bron R, DiCello JJ, Bathgate RAD, Kocan M, Hutchinson DS, Summers RJ.

J Mol Endocrinol. 2018 Apr;60(3):213-224. doi: 10.1530/JME-17-0152.

PMID:
29535183
12.

Informational masking of speech by time-varying competitors: Effects of frequency region and number of interfering formants.

Roberts B, Summers RJ.

J Acoust Soc Am. 2018 Feb;143(2):891. doi: 10.1121/1.5023476.

PMID:
29495741
13.

G Protein-Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus.

Riddy DM, Delerive P, Summers RJ, Sexton PM, Langmead CJ.

Pharmacol Rev. 2018 Jan;70(1):39-67. doi: 10.1124/pr.117.014373. Review.

PMID:
29233848
14.

α1A-Adrenoceptors activate mTOR signalling and glucose uptake in cardiomyocytes.

Sato M, Evans BA, Sandström AL, Chia LY, Mukaida S, Thai BS, Nguyen A, Lim L, Tan CYR, Baltos JA, White PJ, May LT, Hutchinson DS, Summers RJ, Bengtsson T.

Biochem Pharmacol. 2018 Feb;148:27-40. doi: 10.1016/j.bcp.2017.11.016. Epub 2017 Nov 24.

15.

Perception of global image contrast involves transparent spatial filtering and the integration and suppression of local contrasts (not RMS contrast).

Meese TS, Baker DH, Summers RJ.

R Soc Open Sci. 2017 Sep 6;4(9):170285. doi: 10.1098/rsos.170285. eCollection 2017 Sep.

16.

Comment on: Value of flow cytometric analysis of peripheral blood samples in children diagnosed with acute lymphoblastic leukemia.

Summers RJ, Metrock LK, Park S, Gillespie S, Castellino S, Lew G, Keller FG.

Pediatr Blood Cancer. 2017 Oct 8;65(2). doi: 10.1002/pbc.26845. No abstract available.

PMID:
28988416
17.

The PPARγ agonist rosiglitazone promotes the induction of brite adipocytes, increasing β-adrenoceptor-mediated mitochondrial function and glucose uptake.

Merlin J, Sato M, Nowell C, Pakzad M, Fahey R, Gao J, Dehvari N, Summers RJ, Bengtsson T, Evans BA, Hutchinson DS.

Cell Signal. 2018 Jan;42:54-66. doi: 10.1016/j.cellsig.2017.09.023. Epub 2017 Sep 29.

PMID:
28970184
18.

Stream segregation of concurrent speech and the verbal transformation effect: Influence of fundamental frequency and lateralization cues.

Stachurski M, Summers RJ, Roberts B.

Hear Res. 2017 Oct;354:16-27. doi: 10.1016/j.heares.2017.07.016. Epub 2017 Aug 2.

19.

Structure-function analyses of a pertussis-like toxin from pathogenic Escherichia coli reveal a distinct mechanism of inhibition of trimeric G-proteins.

Littler DR, Ang SY, Moriel DG, Kocan M, Kleifeld O, Johnson MD, Tran MT, Paton AW, Paton JC, Summers RJ, Schembri MA, Rossjohn J, Beddoe T.

J Biol Chem. 2017 Sep 8;292(36):15143-15158. doi: 10.1074/jbc.M117.796094. Epub 2017 Jun 29.

20.

ML290 is a biased allosteric agonist at the relaxin receptor RXFP1.

Kocan M, Sarwar M, Ang SY, Xiao J, Marugan JJ, Hossain MA, Wang C, Hutchinson DS, Samuel CS, Agoulnik AI, Bathgate RAD, Summers RJ.

Sci Rep. 2017 Jun 7;7(1):2968. doi: 10.1038/s41598-017-02916-5.

21.

Recent progress in the understanding of relaxin family peptides and their receptors.

Summers RJ.

Br J Pharmacol. 2017 May;174(10):915-920. doi: 10.1111/bph.13778.

22.

Factors influencing biased agonism in recombinant cells expressing the human α1A -adrenoceptor.

da Silva Junior ED, Sato M, Merlin J, Broxton N, Hutchinson DS, Ventura S, Evans BA, Summers RJ.

Br J Pharmacol. 2017 Jul;174(14):2318-2333. doi: 10.1111/bph.13837. Epub 2017 Jun 10.

23.

Utility of peripheral blood immunophenotyping by flow cytometry in the diagnosis of pediatric acute leukemia.

Metrock LK, Summers RJ, Park S, Gillespie S, Castellino S, Lew G, Keller FG.

Pediatr Blood Cancer. 2017 Oct;64(10). doi: 10.1002/pbc.26526. Epub 2017 Mar 23.

PMID:
28333411
24.

WITHDRAWN: Informational masking and the effects of differences in fundamental frequency and fundamental-frequency contour on phonetic integration in a formant ensemble.

Summers RJ, Bailey PJ, Roberts B.

Hear Res. 2017 Jan 18. pii: S0378-5955(16)30380-X. doi: 10.1016/j.heares.2016.10.031. [Epub ahead of print] No abstract available.

PMID:
28110077
25.

High throughput, quantitative analysis of human osteoclast differentiation and activity.

Diepenhorst NA, Nowell CJ, Rueda P, Henriksen K, Pierce T, Cook AE, Pastoureau P, Sabatini M, Charman WN, Christopoulos A, Summers RJ, Sexton PM, Langmead CJ.

Anal Biochem. 2017 Feb 15;519:51-56. doi: 10.1016/j.ab.2016.12.010. Epub 2016 Dec 14.

PMID:
27988276
26.

The actions of relaxin family peptides on signal transduction pathways activated by the relaxin family peptide receptor RXFP4.

Ang SY, Hutchinson DS, Evans BA, Hossain MA, Patil N, Bathgate RA, Kocan M, Summers RJ.

Naunyn Schmiedebergs Arch Pharmacol. 2017 Jan;390(1):105-111. doi: 10.1007/s00210-016-1321-8. Epub 2016 Nov 26.

PMID:
27888281
27.

Isoform-Specific Biased Agonism of Histamine H3 Receptor Agonists.

Riddy DM, Cook AE, Diepenhorst NA, Bosnyak S, Brady R, Mannoury la Cour C, Mocaer E, Summers RJ, Charman WN, Sexton PM, Christopoulos A, Langmead CJ.

Mol Pharmacol. 2017 Feb;91(2):87-99. doi: 10.1124/mol.116.106153. Epub 2016 Nov 18. Erratum in: Mol Pharmacol. 2017 Mar;91(3):263.

PMID:
27864425
28.

Informational masking and the effects of differences in fundamental frequency and fundamental-frequency contour on phonetic integration in a formant ensemble.

Summers RJ, Bailey PJ, Roberts B.

Hear Res. 2017 Feb;344:295-303. doi: 10.1016/j.heares.2016.10.026. Epub 2016 Nov 1.

29.

Molecular pharmacology of G protein-coupled receptors.

Summers RJ.

Br J Pharmacol. 2016 Oct;173(20):2931-3. doi: 10.1111/bph.13610.

30.
31.

Signal transduction pathways activated by insulin-like peptide 5 at the relaxin family peptide RXFP4 receptor.

Ang SY, Hutchinson DS, Patil N, Evans BA, Bathgate RAD, Halls ML, Hossain MA, Summers RJ, Kocan M.

Br J Pharmacol. 2017 May;174(10):1077-1089. doi: 10.1111/bph.13522. Epub 2016 Jul 13. Erratum in: Br J Pharmacol. 2017 Dec;174(24):4836.

32.

A single-chain derivative of the relaxin hormone is a functionally selective agonist of the G protein-coupled receptor, RXFP1.

Hossain MA, Kocan M, Yao ST, Royce SG, Nair VB, Siwek C, Patil NA, Harrison IP, Rosengren KJ, Selemidis S, Summers RJ, Wade JD, Bathgate RAD, Samuel CS.

Chem Sci. 2016 Jun 1;7(6):3805-3819. doi: 10.1039/c5sc04754d. Epub 2016 Feb 26.

33.

The actions of relaxin on the human cardiovascular system.

Sarwar M, Du XJ, Dschietzig TB, Summers RJ.

Br J Pharmacol. 2017 May;174(10):933-949. doi: 10.1111/bph.13523. Epub 2016 Jul 11. Review. Erratum in: Br J Pharmacol. 2017 Dec;174(24):4836.

34.

Antifibrotic Actions of Serelaxin - New Roles for an Old Player.

Samuel CS, Summers RJ, Hewitson TD.

Trends Pharmacol Sci. 2016 Jun;37(6):485-497. doi: 10.1016/j.tips.2016.02.007. Epub 2016 Mar 17. Review.

PMID:
26996448
35.

Engineering of a Novel Simplified Human Insulin-Like Peptide 5 Agonist.

Patil NA, Hughes RA, Rosengren KJ, Kocan M, Ang SY, Tailhades J, Separovic F, Summers RJ, Grosse J, Wade JD, Bathgate RA, Hossain MA.

J Med Chem. 2016 Mar 10;59(5):2118-25. doi: 10.1021/acs.jmedchem.5b01786. Epub 2016 Feb 12.

PMID:
26824523
36.

Murine GPRC6A Mediates Cellular Responses to L-Amino Acids, but Not Osteocalcin Variants.

Rueda P, Harley E, Lu Y, Stewart GD, Fabb S, Diepenhorst N, Cremers B, Rouillon MH, Wehrle I, Geant A, Lamarche G, Leach K, Charman WN, Christopoulos A, Summers RJ, Sexton PM, Langmead CJ.

PLoS One. 2016 Jan 19;11(1):e0146846. doi: 10.1371/journal.pone.0146846. eCollection 2016.

37.

The Time Course of Changes in Retinal Vessel Diameter in Response to Differing Durations of Flicker Light Provocation.

Heitmar R, Summers RJ.

Invest Ophthalmol Vis Sci. 2015 Nov;56(12):7581-8. doi: 10.1167/iovs.15-17089.

PMID:
26618650
38.

Enhanced serelaxin signalling in co-cultures of human primary endothelial and smooth muscle cells.

Sarwar M, Samuel CS, Bathgate RA, Stewart DR, Summers RJ.

Br J Pharmacol. 2016 Feb;173(3):484-96. doi: 10.1111/bph.13371. Epub 2016 Jan 15.

39.

Orthosteric, Allosteric and Biased Signalling at the Relaxin-3 Receptor RXFP3.

Kocan M, Ang SY, Summers RJ.

Neurochem Res. 2016 Mar;41(3):610-9. doi: 10.1007/s11064-015-1701-3. Epub 2015 Aug 21.

PMID:
26294284
40.

Label-Free Kinetics: Exploiting Functional Hemi-Equilibrium to Derive Rate Constants for Muscarinic Receptor Antagonists.

Riddy DM, Valant C, Rueda P, Charman WN, Sexton PM, Summers RJ, Christopoulos A, Langmead CJ.

Mol Pharmacol. 2015 Oct;88(4):779-90. doi: 10.1124/mol.115.100545. Epub 2015 Aug 4.

PMID:
26243731
41.

Informational masking of monaural target speech by a single contralateral formant.

Roberts B, Summers RJ.

J Acoust Soc Am. 2015 May;137(5):2726-36. doi: 10.1121/1.4919344.

PMID:
25994702
43.

Acoustic source characteristics, across-formant integration, and speech intelligibility under competitive conditions.

Roberts B, Summers RJ, Bailey PJ.

J Exp Psychol Hum Percept Perform. 2015 Jun;41(3):680-91. doi: 10.1037/xhp0000038. Epub 2015 Mar 9.

44.

The verbal transformation effect and the perceptual organization of speech: influence of formant transitions and F0-contour continuity.

Stachurski M, Summers RJ, Roberts B.

Hear Res. 2015 May;323:22-31. doi: 10.1016/j.heares.2015.01.007. Epub 2015 Jan 22.

45.

Area summation of first- and second-order modulations of luminance.

Summers RJ, Baker DH, Meese TS.

J Vis. 2015 Jan 14;15(1):15.1.12. doi: 10.1167/15.1.12.

PMID:
25589296
46.

Response to Comment on Sato et al. Improving type 2 diabetes through a distinct adrenergic signaling pathway involving mTORC2 that mediates glucose uptake in skeletal muscle. Diabetes 2014;63:4115-4129.

Sato M, Dehvari N, Oberg AI, Summers RJ, Hutchinson DS, Bengtsson T.

Diabetes. 2014 Dec;63(12):e22-3. doi: 10.2337/db14-1283. No abstract available.

47.

Serelaxin-mediated signal transduction in human vascular cells: bell-shaped concentration-response curves reflect differential coupling to G proteins.

Sarwar M, Samuel CS, Bathgate RA, Stewart DR, Summers RJ.

Br J Pharmacol. 2015 Feb;172(4):1005-19. doi: 10.1111/bph.12964. Epub 2014 Dec 1.

48.

Improving type 2 diabetes through a distinct adrenergic signaling pathway involving mTORC2 that mediates glucose uptake in skeletal muscle.

Sato M, Dehvari N, Oberg AI, Dallner OS, Sandström AL, Olsen JM, Csikasz RI, Summers RJ, Hutchinson DS, Bengtsson T.

Diabetes. 2014 Dec;63(12):4115-29. doi: 10.2337/db13-1860. Epub 2014 Jul 9.

49.

Formant-frequency variation and informational masking of speech by extraneous formants: evidence against dynamic and speech-specific acoustical constraints.

Roberts B, Summers RJ, Bailey PJ.

J Exp Psychol Hum Percept Perform. 2014 Aug;40(4):1507-25. doi: 10.1037/a0036629. Epub 2014 May 19.

50.

Signalling profiles of H3 relaxin, H2 relaxin and R3(BΔ23-27)R/I5 acting at the relaxin family peptide receptor 3 (RXFP3).

Kocan M, Sarwar M, Hossain MA, Wade JD, Summers RJ.

Br J Pharmacol. 2014 Jun;171(11):2827-41. doi: 10.1111/bph.12623.

Supplemental Content

Loading ...
Support Center